Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 Dichloride, Peposertib, and Avelumab in Advanced mCRPC
NCT04071236Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2020
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peposertib in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Dose-limiting toxicity at 28 days and Radiographic progression free survival up to 2 years. Started Oct 2020; status: active, not recruiting.
02
Drugs
peposertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04071236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071236.